文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Establishment and validation of a nomogram for predicting IDH-wildtype glioblastomas in nonenhancing adult-type diffuse gliomas.

作者信息

He Lei, Fei Fan, Zhou Chengzhi, Bai Xiaoyan, Yu Shuqing, Wang Lei, Xu Ruxiang, Liu Hanjie

机构信息

Department of Neurosurgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

出版信息

Neurooncol Adv. 2025 Feb 8;7(1):vdaf035. doi: 10.1093/noajnl/vdaf035. eCollection 2025 Jan-Dec.


DOI:10.1093/noajnl/vdaf035
PMID:40321617
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12048881/
Abstract

BACKGROUND: Approximately 8.94%-44.44% of nonenhancing adult-type diffuse gliomas are identified as glioblastomas. Our purpose is to develop a nomogram that can predict glioblastomas from nonenhancing adult-type diffuse gliomas. METHODS: Nonenhancing adult-type diffuse gliomas were collected from Beijing Tiantan Hospital and TCIA public database. Univariate and multivariate logistic regression were performed to screen features on the training set. The features with  < .05 in multivariate logistic regression were used to establish the prediction model. The testing and validation sets were used to test the model. RESULTS: A total of 557 and 67 nonenhancing adult-type diffuse gliomas were collected from Beijing Tiantan Hospital and TCIA, respectively. The T2-FLAIR mismatch sign exhibited 100% specificity but low sensitivity (<30%) in ruling out glioblastoma. Age, tumor location, rADC, and rADC were identified as independent predictors and employed for developing the prediction model. The AUC of the model was 0.901, 0.861, and 0.945 in the training, testing, and validation set, respectively. The best cutoff value of nomoscore was 138.5, which achieved sensitivity of 0.935, 0.714, and 0.895, specificity of 0.777, 0.782, and 0.8775 in the training, testing, and validation sets, respectively. Survival analysis shown that patients with nomoscore above 138.5 had significantly poorer survival time than those with scores below 138.5. CONCLUSIONS: Positive T2-FLAIR mismatch sign can effectively rule out glioblastoma in nonenhancing adult-type diffuse gliomas with high specificity. Nonenhancing adult-type diffuse gliomas with nomoscore above 138.5 are highly suspicious for glioblastoma or nonglioblastoma with a poor prognosis.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/706f/12048881/094863de4753/vdaf035_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/706f/12048881/032624e47d7f/vdaf035_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/706f/12048881/250305abc941/vdaf035_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/706f/12048881/d153965e6875/vdaf035_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/706f/12048881/094863de4753/vdaf035_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/706f/12048881/032624e47d7f/vdaf035_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/706f/12048881/250305abc941/vdaf035_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/706f/12048881/d153965e6875/vdaf035_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/706f/12048881/094863de4753/vdaf035_fig4.jpg

相似文献

[1]
Establishment and validation of a nomogram for predicting IDH-wildtype glioblastomas in nonenhancing adult-type diffuse gliomas.

Neurooncol Adv. 2025-2-8

[2]
Cortical nonenhancing tumor infiltration: a predictive imaging biomarker for IDH-mutant glioma.

J Neurosurg. 2025-4-4

[3]
Identifying IDH-mutant and 1p/19q noncodeleted astrocytomas from nonenhancing gliomas: Manual recognition followed by artificial intelligence recognition.

Neurooncol Adv. 2024-2-1

[4]
Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.

AJNR Am J Neuroradiol. 2024-2-7

[5]
Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.

Eur Radiol. 2019-8-24

[6]
MRI Scoring Systems for Predicting Isocitrate Dehydrogenase Mutation and Chromosome 1p/19q Codeletion in Adult-type Diffuse Glioma Lacking Contrast Enhancement.

Radiology. 2024-5

[7]
The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.

Neurosurg Focus. 2019-12-1

[8]
T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology.

Neurooncol Adv. 2020-1-10

[9]
Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.

Eur Radiol. 2021-10

[10]
Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas.

Ann Clin Transl Neurol. 2025-2

本文引用的文献

[1]
MRI Scoring Systems for Predicting Isocitrate Dehydrogenase Mutation and Chromosome 1p/19q Codeletion in Adult-type Diffuse Glioma Lacking Contrast Enhancement.

Radiology. 2024-5

[2]
Preoperative growth dynamics of untreated glioblastoma: Description of an exponential growth type, correlating factors, and association with postoperative survival.

Neurooncol Adv. 2024-4-3

[3]
Identifying IDH-mutant and 1p/19q noncodeleted astrocytomas from nonenhancing gliomas: Manual recognition followed by artificial intelligence recognition.

Neurooncol Adv. 2024-2-1

[4]
Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era.

Neuro Oncol. 2024-1-5

[5]
Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.

Eur Radiol. 2024-2

[6]
Risk Estimation in Non-Enhancing Glioma: Introducing a Clinical Score.

Cancers (Basel). 2023-4-27

[7]
The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1-Key Points of the Fifth Edition and Summary of Imaging Findings on Adult-Type Diffuse Gliomas.

J Magn Reson Imaging. 2023-9

[8]
The sinuous, wave-like intratumoral-wall sign is a sensitive and specific radiological biomarker for oligodendrogliomas.

Eur Radiol. 2023-6

[9]
Noninvasive differentiation of molecular subtypes of adult nonenhancing glioma using MRI perfusion and diffusion parameters.

Neurooncol Adv. 2022-2-21

[10]
Predictive accuracy of T2-FLAIR mismatch sign for the IDH-mutant, 1p/19q noncodeleted low-grade glioma: An updated systematic review and meta-analysis.

Neurooncol Adv. 2022-1-27

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索